|Generic name||Anagrelide hydrochloride|
|Brand name(s), other common name(s)||Agrylin®|
|Drug type||Platelet-reducing agent|
|How the drug is given||By mouth|
Anagrelide hydrochloride is FDA approved for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to improve associated symptoms including thrombo-hemorrhagic events (a process that involves either a blood clot or bleeding, such as a heart attack or stroke).
Side effects needing medical attention:Lack of strength; headache; fever; malaise; pain; abdominal pain; palpitations; faster than normal heartbeat; anorexia; diarrhea; indigestion; flatulence; nausea; vomiting; edema; dizziness; paresthesia (a skin sensation, such as burning, prickling, itching, or tingling, with no apparent physical cause); cough; shortness of breath; sore throat; itchy skin; rash.